Clinical advancements in psoriasis treatment are underway with the introduction of second-generation phosphodiesterase 4 (PDE4) inhibitors, notably orismilast. This new oral medication aims to...
Patients diagnosed with psoriasis are encountering significant barriers between their treatment eligibility and actual access to advanced therapies. Despite a broader array of treatment...
Patients suffering from moderate to severe psoriasis are witnessing significant developments in treatment options tailored to their specific needs. The range of therapies includes...
Psoriasis is recognized as the second most common autoimmune condition in the United States, affecting millions of individuals. This condition is not merely a...